Pertussis Medication: Antibiotics, Other, Vaccines, Inactivated, Bacterial (original) (raw)

Medication Summary

Antimicrobial agents given during the catarrhal phase may ameliorate the disease. Once cough is established, antimicrobial agents may not alter the course of the illness but still are recommended to limit the spread of disease.

Pertussis-specific immunoglobulin is an investigational product that may be effective in decreasing paroxysms of cough, although it requires further evaluation.

The use of corticosteroids, albuterol, and other beta2-adrenergic agents for the treatment of pertussis is not supported by controlled, prospective data.

Antibiotics, Other

Class Summary

The Committee on Infectious Diseases (COID) of the American Academy of Pediatrics (Red Book Committee) recommends promptly treating all household and other close contacts (eg, children and staff at daycare centers) with erythromycin to limit secondary transmission. [44] This is regardless of the age or immunization status of contacts.

A 14-day course of oral erythromycin is the antimicrobial therapy of choice for patients with pertussis and for close contacts. Typical dosing schedule is 40-50 mg/kg/day (not to exceed 2 g/day) in 4 divided doses. Some experts prefer the estolate preparation in young infants because of more effective absorption, which may lead to decreased dosing and less frequent dosing intervals.

Erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin)

View full drug information

Erythromycin inhibits bacterial growth, possibly by blocking the dissociation of peptidyl transfer ribonucleic acid (tRNA) from ribosomes, causing RNA-dependent protein synthesis to arrest.

Erythromycin estolate is the antibiotic of choice to prevent interpersonal transfer, because of enhanced absorption, particularly in young infants. (Its effectiveness in prophylaxis for exposed and susceptible persons has not been determined.)

Erythromycin is recommended for household and close contacts (50 mg/kg/day PO qid for 14 days). It is effective in reducing the course and symptoms of pertussis if it is started within the first 10-14 days, but its efficacy has not been proven beyond this period.

Azithromycin (Zithromax, Zmax)

View full drug information

Azithromycin inhibits bacterial growth, possibly by blocking the dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. It has been shown in several small studies to be effective against pertussis.

Clarithromycin (Biaxin)

View full drug information

Clarithromycin inhibits bacterial growth, possibly by blocking the dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. It has been shown in small studies to be effective against pertussis.

Trimethoprim-sulfamethoxazole (Bactrim, Bactrim DS, Septra DS)

View full drug information

This agent inhibits bacterial growth by inhibiting the synthesis of dihydrofolic acid. It can be used as an alternative treatment.

Vaccines, Inactivated, Bacterial

Class Summary

Active immunization increases resistance to infection. Vaccines consist of microorganisms or cellular components that act as antigens. Administration of the vaccine stimulates the production of antibodies with specific protective properties.

The need for prevention of pertussis through immunization cannot be overemphasized. All children younger than 7 years should receive the pertussis vaccine. In the United States, acellular pertussis vaccine is recommended and usually is combined with diphtheria and tetanus toxoids (DTaP). When possible, the same DTaP vaccine product should be used for the first 3 doses of the pertussis immunization series. Reduced-volume dosing is not recommended. Measurable antibody wanes after 3-5 years and is not measurable 12 years after vaccination has been completed. The vaccine may not prevent the illness entirely, but it has been shown to lessen disease severity and duration.

Adolescents and adults have been identified as the source of pertussis transmission to infants, from household contact studies and outbreak investigations. In February 2012, the CDC Advisory Committee on Immunization Practices (ACIP) recommended the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine for all adults, including those aged 65 years or older, and pregnant women.

A Cochrane Database of Systematic Reviews study comparing the safety and efficacy of whole-cell pertussis vaccines with acellular pertussis vaccines in children up to age 6 years found that not only are multi-component acellular pertussis vaccines effective, they show less adverse effects than whole-cell vaccines for primary and booster doses. [45]

The American Academy of Pediatrics approved recommendations from the Committee on Infectious Diseases (COID) for universal vaccination of adolescents at the 11-year or 12-year visit to boost protection against pertussis. [34, 35] The FDA has licensed 2 Tdap vaccines for use in patients aged 10 years or older (Boostrix; GlaxoSmithKline Biologicals, Rixensart, Belgium) and those aged 10-64 years (Adacel; Sanofi Pasteur, Toronto, Canada). Tdap has replaced tetanus in the childhood and adult immunization schedules. It has been shown to be effective in outbreaks in the short term. Long-term effectiveness studies are ongoing.

Compared with children who have been vaccinated, children of parents who refuse pertussis immunizations are at high risk for pertussis infection. A case-control study identified 156 laboratory-confirmed pertussis cases over an 11-year period (matched controls n=595). [46] Among the cases, 18 (12%) children did not receive the pertussis vaccine; among the controls, 3 (0.5%) children did not receive the pertussis vaccine. A secondary case-control analysis confirmed these results.

The study was performed within the Kaiser Permanente system of Colorado, where 11% of all pertussis cases within the system were attributed to parental vaccine refusal. Herd immunity does not seem to completely protect unvaccinated children from pertussis.

The latest vaccine recommendations can be found at the CDC Immunization Schedule Website. [47]

Diphtheria & tetanus toxoids/ acellular pertussis vaccine (Daptacel, Infanrix)

View full drug information

DTaP (Daptacel, Infanrix) promotes active immunity to diphtheria, tetanus, and pertussis by inducing production of specific antibodies and antitoxins.

In children and adults, DTaP may be administered into the deltoid or midlateral thigh muscles. In infants, the preferred site of administration is the mid-thigh, laterally.

Tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine (Adacel, Boostrix, Tdap)

View full drug information

Promotes active immunity to diphtheria, tetanus, and pertussis by inducing the production of specific neutralizing antibodies and antitoxins. It is indicated for active booster immunization for persons aged 10 or older (Adacel approved for aged 10-64 y, Boostrix approved for aged 10 y or older). It is the preferred vaccine for adolescents scheduled for a booster vaccination.

It also is indicated to prevent pertussis in infants younger than 2 months by immunizing pregnant females during the third trimester of pregnancy.

Robinson CL, Romero JR, Kempe A, Pellegrini C, Advisory Committee on Immunization Practices (ACIP) Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Feb 10. 66 (5):134-135. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Feb 10. 66 (5):136-138. [QxMD MEDLINE Link].
Outbreaks of respiratory illness mistakenly attributed to pertussis--New Hampshire, Massachusetts, and Tennessee, 2004-2006. MMWR Morb Mortal Wkly Rep. 2007 Aug 24. 56(33):837-42. [QxMD MEDLINE Link].
Marconi GP, Ross LA, Nager AL. An upsurge in pertussis: epidemiology and trends. Pediatr Emerg Care. 2012 Mar. 28(3):215-9. [QxMD MEDLINE Link].
Walsh PF, Kimmel L, Feola M, Tran T, Lim C, De Salvia L, et al. Prevalence of Bordetella pertussis and Bordetella parapertussis in infants presenting to the emergency department with bronchiolitis. J Emerg Med. 2011 Mar. 40(3):256-61. [QxMD MEDLINE Link].
Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, et al. Infant pertussis: who was the source?. Pediatr Infect Dis J. 2004 Nov. 23(11):985-9. [QxMD MEDLINE Link].
Skoff TH, Kenyon C, Cocoros N, Liko J, Miller L, Kudish K, et al. Sources of Infant Pertussis Infection in the United States. Pediatrics. 2015 Sep 7. [QxMD MEDLINE Link].
Skwarecki B. Infants More Likely to Contract Pertussis From Siblings. https://www.medscape.com/viewarticle/850781\. Available at https://www.medscape.com/viewarticle/850781. September 10, 2015; Accessed: September 14, 2015.
Liu BC, McIntyre P, Kaldor JM, Quinn H, Ridda I, Banks E. Pertussis in older adults: prospective study of risk factors and morbidity. Clin Infect Dis. 2012 Jul 26. [QxMD MEDLINE Link].
Cherry JD, Heininger U. Pertussis and other Bordetella Infections. In: Feigin RD, Demmler GJ, Cherry JD, Kaplan SL. Textbook of Pediatric Infectious Diseases. Vol 1. 5th ed. Philadelphia, PA: WB Saunders Co.; 2004:1588-1608:
Notes from the field : use of tetanus, diphtheria, and pertussis vaccine (Tdap) in an Emergency Department - Arizona, 2009-2010. MMWR Morb Mortal Wkly Rep. 2012 Jan 27. 61(3):55-6. [QxMD MEDLINE Link].
Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, et al. California Pertussis Epidemic, 2010. J Pediatr. 2012 Jul 20. [QxMD MEDLINE Link].
Pertussis epidemic - washington, 2012. MMWR Morb Mortal Wkly Rep. 2012 Jul 20. 61:517-22. [QxMD MEDLINE Link].
Pertussis--United States, 2001-2003. MMWR Morb Mortal Wkly Rep. 2005 Dec 23. 54(50):1283-6. [QxMD MEDLINE Link].
Centers for Disease Control. Pertussis. In: Atkinson W, Wolfe S, Hamborsky. J. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed. Washington DC: Public Health Foundation; 2012:215-231:[Full Text].
Centers for Disease Control and Prevention. Pertussis (Whooping Cough): Outbreaks. Available at https://www.cdc.gov/pertussis/outbreaks.html. Accessed: Aug 9, 2012.
Centers for Disease Control and Prevention. Pertussis (Whooping Cough): Surveillance and Reporting. Available at https://www.cdc.gov/pertussis/surv-reporting.html. Accessed: Aug 10, 2012.
Christensen J. California declares whooping cough epidemic. CNN.com. Available at https://www.cnn.com/2014/06/13/health/whooping-cough-california/. Accessed: June 17, 2014.
Atwell JE, Van Otterloo J, Zipprich J, Winter K, Harriman K, Salmon DA. Nonmedical vaccine exemptions and pertussis in California, 2010. Pediatrics. 2013 Oct. 132(4):624-30. [QxMD MEDLINE Link].
CDC. Pertussis Outbreak Trends. CDC.gov. Available at https://www.cdc.gov/pertussis/outbreaks/trends.html. Accessed: June 17, 2014.
Barclay L. Pertussis Cases Near 10,000 in California This Year. Medscape Medical News. Available at https://www.medscape.com/viewarticle/835898. Accessed: December 5, 2014.
Winter K, Glaser C, Watt J, et al. Pertussis Epidemic — California, 2014. Morb Mortal Wkly Rep. 2014. 63:1129-1132. [Full Text].
Bettiol S, Thompson MJ, Roberts NW, Perera R, Heneghan CJ, Harnden A. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev. 2010 Jan 20. CD003257. [QxMD MEDLINE Link].
Nitsch-Osuch A, Kuchar E, Modrzejewska G, Pirogowicz I, Zycinska K, Wardyn K. Epidemiology of Pertussis in an Urban Region of Poland: Time for a Booster for Adolescents and Adults. Adv Exp Med Biol. 2013. 755:203-212. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention. Pertussis--United States, 2001-2003 MMWR Morb Mortal Wkly Rep. Dec 23, 2005;54(50):1283-6. Available at https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5450a3.htm. Accessed: Aug 9, 2012.
Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005 Apr. 18(2):326-82. [QxMD MEDLINE Link]. [Full Text].
Bisgard K. Background. Guidelines for the Control of Pertussis Outbreaks. 2000;1-1-1-11:[Full Text].
Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J. 2003 Jul. 22(7):628-34. [QxMD MEDLINE Link].
Guinto-Ocampo H, Bennett JE, Attia MW. Predicting pertussis in infants. Pediatr Emerg Care. 2008 Jan. 24(1):16-20. [QxMD MEDLINE Link].
Waknine Y. Infant Pertussis: Early White Blood Cell Counts Crucial. Available at https://www.medscape.com/viewarticle/777732. Accessed: January 23, 2013.
Murray E, Nieves D, Bradley J, et al. Characteristics of Severe Bordetella pertussis Infection Among Infants Older than 90 Days of Age Admitted to Pediatric Intensive Care Units – Southern California, September 2009–June 2011. J Ped Infect Dis. 2013.
Edwards K, Decker MD. Pertussis vaccine. In: Plotkin SA, Orenstein WA. Vaccines. 4th ed. Philadelphia, PA: Saunders; 2004:471-528.
de Greeff SC, Mooi FR, Westerhof A, Verbakel JM, Peeters MF, Heuvelman CJ, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis. 2010 May 15. 50(10):1339-45. [QxMD MEDLINE Link].
[Guideline] American Academy of Pediatric Committee on Infectious Diseases. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics. 2006 Mar. 117(3):965-78. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention; American Academy of Pediatrics Committee on Infectious Diseases. Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Pediatrics. 2011 Oct. 128(4):809-12. [QxMD MEDLINE Link].
Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged MMWR Morb Mortal Wkly Rep. 2011 Oct 21. 60(41):1424-6. [QxMD MEDLINE Link].
McNamara LA, Skoff T, Faulkner A, Miller L, Kudish K, Kenyon C, et al. Reduced Severity of Pertussis in Persons With Age-Appropriate Pertussis Vaccination-United States, 2010-2012. Clin Infect Dis. 2017 Sep 1. 65 (5):811-818. [QxMD MEDLINE Link].
Harding A. Pertussis Vaccine Appears Safe in Pregnancy for Mom, Baby. Medscape Medical News. Available at https://www.medscape.com/viewarticle/834849. Accessed: November 14, 2014.
Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway A, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA. 2014 Nov 12. 312(18):1897-904. [QxMD MEDLINE Link].
Skoff TH, Blain AE, Watt J, Scherzinger K, McMahon M, Zansky SM, et al. Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants Clin Infect Dis. 2017 Sep 28. [QxMD MEDLINE Link].
Kent A, Ladhani SN, Andrews NJ, et al. Pertussis Antibody Concentrations in Infants Born Prematurely to Mothers Vaccinated in Pregnancy. Pediatrics. Online: June 2016:
Pregnant Women and Tdap Vaccination, Internet Panel Survey, United States, April 2016. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/tdap-report-2016.html. September 19, 2016; Accessed: October 20, 2017.
Recommended childhood and adolescent immunization schedule--United States, 2014. Pediatrics. 2014 Feb. 133(2):357-63. [QxMD MEDLINE Link].
American Academy of Pediatrics. Pickering LK, ed. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.
Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2011 Jan 19. CD001478. [QxMD MEDLINE Link].
Glanz JM, McClure DL, Magid DJ, Daley MF, France EK, Salmon DA, et al. Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. Pediatrics. 2009 Jun. 123(6):1446-51. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention. Immunization Schedules. Available at https://www.cdc.gov/vaccines/schedules/index.html. Accessed: Aug 9, 2012.
Brown T. Pertussis vaccines: whole-cell more durable than acellular. Medscape Medical News. May 22, 2013. [Full Text].
Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers. Pediatrics. 2013 May 20. [QxMD MEDLINE Link].
New S, Winter K, Boyte R, Harriman K, Gutman A, Christiansen A, et al. Barriers to Receipt of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Among Mothers of Infants Aged MMWR Morb Mortal Wkly Rep. 2018 Sep 28. 67 (38):1068-1071. [QxMD MEDLINE Link].
Pitisuttithum P, Chokephaibulkit K, Sirivichayakul C, et al. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2018 Sep 25. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013 Feb 22. 62 (7):131-5. [QxMD MEDLINE Link]. [Full Text].
WHO. Leading health agencies outline updated terminology for pathogens that transmit through the air. World Health Organization. Available at https://www.who.int/news/item/18-04-2024-leading-health-agencies-outline-updated-terminology-for-pathogens-that-transmit-through-the-air. April 18,2024; Accessed: April 25, 2024.
Wodi AP, Issa AN, Moser CA, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025. MMWR. January 16, 2025. 74(2):30-33. [Full Text].
Issa AN, Wodi AP, Moser DA, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025. MMWR. January 16, 2025. 74(2):26-29. [Full Text].

Author

Coauthor(s)

Bryon K McNeil, MD Medical Director, Bioterrorism and Emergency Preparedness, Clinical Assistant Professor, Departments of Internal Medicine and Emergency Medicine, Via Christ Regional Medical Center

Bryon K McNeil, MD is a member of the following medical societies: American Academy of Emergency Medicine, Pennsylvania Medical Society